Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    Phase III: Screening Study for Alzheimer’s disease studies

    Clinical Trial Overview

    Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

    Objective

    This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

    Primary Endpoints

    • Concentration of pTau217 in Blood on Day 1
    • Cognitive score in ISLT on Day 1

    Secondary Endpoints

    • N/A

    ISLT=International Shopping List Test

    N/A

    Modality: Non-interventional

    View Details
    View Related Trials

    QUICK LINKS

    Molecule
    Clinical Trial Overview
    Inclusion and Exclusion Criteria
    Enrollment and Resources
    Related Trials
    Contact an MSL
    View on ClinicalTrials.gov

    Inclusion and Exclusion Criteria

    Key Inclusion Criteria Key Exclusion Criteria
    • Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD
    • Dependency in basic activities of daily living (bADLs) due to cognitive impairment
    • Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
    • Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
    • History of severe, clinically significant central nervous system trauma
    • Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

    AD=Alzheimer’s disease; bADLs=basic activities of daily living; MCI=mild cognitive impairment

    Enrollment & Resources

    Enrollment

    For more information on eligibility criteria, view the study or reach out to our team.

    General icon

    Web

    ClinicalTrials.gov
    Identifier: NCT07177352

    Visit Site
    Call icon

    Phone

    1-888-662-6728
    (US and Canada)

    Call Us
    Email icon

    Email

    [email protected]

    Email Us

    Clinical Trial Site Locations

    Clinical Trial Site Locations

    For more information on recruitment status, or where the study is being conducted

    Visit ClinicalTrials.gov

    Patient Resources

    Genentech offers a place for patients, relatives, and caregivers to learn more about clinical trials.

    Visit Site

    Information is consistent with ClinicalTrials.gov as of February 2, 2026. Products under investigation have not been approved for use outside of the clinical trial setting. This information is presented only for the purposes of providing an overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes.

    Looking for more information?

    Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

    Connect with an MSL
    Submit a Request

    Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT

    TOP

    • AD
      Alzheimer’s disease

    • bADLs
      Basic activities of daily living

    • ISLT
      International Shopping List Test

    • MCI
      Mild cognitive impairment